Form D · Pharmaceuticals

Vimy Pharmaceuticals Inc.

Toronto, A6 · CIK 0002159983

Offering snapshot reported Oct 13, 2026 · SEC filing

Reported sold: $1.01M
Investors reported: 7
Minimum accepted: $0
First sale: Sep 28, 2026

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Oct 13, 2026	Initial	$1,010,798	No comparison	7	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: Yes

Sales commissions: $150K (estimated)
Finders' fees: $0
Form D file number: 021-601025

The total offering amount was $1,432,200 in Canadian dollars. The U.S. dollar value above is based on the Federal Reserve exchange rate on September 28, 2026 of $1.4169 CAD per USD.

Consists of (i) $34,583 cash fee; (ii) President's List purchasers: $2,757 cash fee and $2,757 in options, each 3% of such sales; (iii) other purchasers: $55,134 cash fee and $55,134 in options, each 6% of such sales. CAD converted to USD at the same rate

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Beacon Securities US Limited	000306613	Beacon Securities Limited

Source: Form D, filed Oct 13, 2026. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Christopher Burkett	Director
Darryl Firsten	Director
Farris Smith	Director, Executive
David John Suchon	Director, Executive
Riccardo Trecroce	Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

2 Bloor Street West Suite 2002
Toronto, A6, M4W1J5